Clinical trials: Lipids, open to volunteers
Familial Chylomicronemia Syndrome (FCS)
CS-121 APOC3 Base Editing in FCS
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid…
- Trial name
- NCT07176923
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Gaucher Disease, Type I, Gaucher Disease, Type III
Gaucherite - A Study to Stratify Gaucher Disease
The purpose of this research is to review data already collected and to collect new data from adults and children in England with Gaucher Disease to determine clinical factors which predict severity and response to therapy of…
- Trial name
- Gaucherite (NCT03240653)
- Testing
- Stratified response to Enzyme Therapy
- Where
- 8 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Overweight and Obese Adults, High Intensity Interval Exercise (HIIE)
Acute Effects of Isoenergetic HIIE vs. MICE on Key Parameters of Fat Mass Loss in Young Females With Overweight or Obesity
Overweight and obesity, particularly increased total and/or abdominal fat mass (FM), are strongly linked to the development of cardiovascular diseases.
- Trial name
- COMEFIT (NCT06868862)
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
Epilepsy, Dyslipidemia
Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet
Ketogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications.
- Trial name
- NCT06369571
- Testing
- Atorvastatin 10mg, Modification of dietary fat composition
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Fabry Disease
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene.
- Trial name
- NCT05698901
- Testing
- Agalsidase beta
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Mackay Memorial Hospital
Time Restricted Eating, Obstructive Sleep Apnea
Time Restricted Eating in Sleep Apnea
Obstructive sleep apnea (OSA) is a highly prevalent disorder that is associated with both cardiovascular and metabolic dysfunction, such as hypertension, increased blood glucose levels and diabetes, obesity, and nonalcoholic…
- Trial name
- TERESA (NCT06047496)
- Testing
- Time restricted eating
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Diego
Stroke
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
EAST-LDL is a prospective, multicenter, randomized, open-label clinical trial with blinded endpoint assessment evaluating whether early intensive lipid lowering with the PCSK9 inhibitor recaticimab, administered before…
- Trial name
- EAST-LDL (NCT07002476)
- Testing
- guideline-recommended SoC, Recaticimab (intensive)
- Where
- China
- Volunteers
- 978 people
- Sponsor
- Shanghai East Hospital
Cardio-vascular Disease, Depression Disorders
Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland
In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland.
- Conditions
- Cardio-vascular Disease, Depression Disorders, Diabetes, COPD
- Trial name
- myCare Start-I (NCT07036471)
- Testing
- myCare Start
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- University of Geneva, Switzerland
Familial Hypercholesterolaemia
Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia
The goal of this clinical trial is to learn if a computer alert can aid clinicians in identifying patients with a genetic type of high cholesterol, called Familial Hypercholesterolemia.
- Trial name
- FH-ALERT (NCT06743659)
- Testing
- Alert-based computerized decision support
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Brigham and Women's Hospital
Gaucher Disease, Gaucher Disease Type 1
Study of Velaglucerase Beta ERT in Children With Gaucher Disease
This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.
- Conditions
- Gaucher Disease, Gaucher Disease Type 1, Gaucher Disease Type 3
- Trial name
- NCT07847411
- Testing
- Velaglucerase beta
- Where
- China
- Volunteers
- 10 people
- Sponsor
- CANbridge Life Sciences Ltd.
Healthy Participants, Hyperlipidemia
A Phase 1 Study of VELA-101 in Adult Participants
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses…
- Trial name
- NCT07864311
- Testing
- VELA-101
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ursa Medicines
Ischemic Cardiovascular Disease, Hypertension
Effect of Smartphone Application (MED-AD) on Medication Adherence Among Patients With Cardiovascular Disease in Oman
This study aims to: 1. Investigate the impact of MED-AD intervention on medication adherence among CVD patients, compared to patients receiving text message reminders or routine care alone at baseline, 6 months, and 12 months…
- Conditions
- Ischemic Cardiovascular Disease, Hypertension, Hyperlipidemia
- Trial name
- NCT06951451
- Testing
- smartphone application (MED-AD), Short Text-message Reminders
- Where
- Oman
- Volunteers
- 1,000 people
- Sponsor
- Sultan Qaboos University
Neuronal Ceroid Lipofuscinosis
Italian NCL Registry: a Registry for NCL as an Integration Tool for Future Therapeutic Strategies
The goal is to create a solid and harmonious disease registry of patient affected by neuronal ceroid lipofuscinosis (NCLs) that facilitates the collection and management of patients' data over time encouraging the research and…
- Trial name
- NCT06844877
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Fondazione Stella Maris
Hypercholesterolemia
A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors.
- Trial name
- NCT07404553
- Testing
- SHR-1918 Injection
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Obesity & Overweight, Metabolic Syndrome
Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome
Dietary fiber are components in foods that are not digested by human gastrointestinal enzymes (alpha amylase and alpha glucosidase) but are instead broken down and fermented by gut microbes.
- Conditions
- Obesity & Overweight, Metabolic Syndrome, Gut Dysbiosis, Insulin Resistance
- Trial name
- KMGMS (NCT07703371)
- Testing
- Kodo Millet Porridge Beverage
- Where
- India
- Volunteers
- 50 people
- Sponsor
- JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
To evaluate the efficacy, safety and immunogenicity of QCL7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering…
- Trial name
- NCT07441317
- Testing
- QLC7401
- Volunteers
- 780 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hyperlipidemias, Nephrotic Syndrome
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
Nephrotic syndrome (NS) is characterized by gross proteinuria (>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.
- Trial name
- PCSK9 (NCT06373913)
- Where
- Denmark
- Volunteers
- 75 people
- Sponsor
- Kolding Sygehus
Morbid Obesity, Type2diabetes
Comorbidities Resolution After MGB Surgery and Change in Body Composition
This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients.
- Conditions
- Morbid Obesity, Type2diabetes, Sleep Apnea, Hypothyroidism
- Trial name
- MOGAMBO (NCT06015620)
- Testing
- Mini gastric bypass surgery
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Prediabetes, Diabetes
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides…
- Conditions
- Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight
- Trial name
- NCT06988462
- Testing
- Bottarga, Comparator
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cambridge Health Alliance